Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus BacteremiaPRNewsWire • Tuesday
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 09/12/24
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferencePRNewsWire • 09/05/24
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research SymposiumPRNewsWire • 08/26/24
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial OfficerPRNewsWire • 08/15/24
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdatePRNewsWire • 08/13/24
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02PRNewsWire • 07/30/24
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionPRNewsWire • 07/11/24
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate UpdatePRNewsWire • 05/07/24
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate UpdatePRNewsWire • 03/21/24
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaPRNewsWire • 03/04/24
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy SummitPRNewsWire • 02/21/24
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdatePRNewsWire • 11/14/23
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis ConferencePRNewsWire • 10/30/23
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023PRNewsWire • 10/19/23
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureusPRNewsWire • 09/26/23
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare ConferencePRNewsWire • 09/21/23
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 08/17/23
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate UpdatePRNewsWire • 08/14/23
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage TherapyPRNewsWire • 05/31/23
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/23
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate UpdatePRNewsWire • 05/11/23